Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis

被引:40
|
作者
Miller, Elzbieta [1 ,2 ]
Morel, Agnieszka [3 ]
Redlicka, Justyna [1 ,2 ]
Miller, Igor [1 ]
Saluk, Joanna [3 ]
机构
[1] Med Univ Lodz, Dept Phys Med, Pl Hallera 1, Lodz, Poland
[2] 3rd Gen Hosp Lodz, Neurorehabil Ward, Milionowa 14, Lodz, Poland
[3] Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biochem, Pomorska 141-143, Lodz, Poland
关键词
Multiple sclerosis; cognitive impairment; pharmacology; non-pharmacological therapies; disease-modifying drugs; neurodegeneration; DEEP-BRAIN-STIMULATION; AEROBIC EXERCISE; WHITE-MATTER; DISEASE; MEMORY; LESIONS; RECOMMENDATIONS; PATHOGENESIS; ENHANCEMENT; MULTICENTER;
D O I
10.2174/1570159X15666171109132650
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Cognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency; however, the cognitive MS domain is information processing speed. It is the first syndrome of cognitive dysfunction and the most widely affected in MS. Occasionally these impairments occur even before the appearance of physical symptoms. Methods: Therefore, this review focused on the current status of our knowledge about possible methods of treatment cognitive impairment in MS patients including novel strategies. Research and online content was performed using Medline and EMBASE databases. Results: The most recent research suggests that cognitive impairment is correlated with brain lesion volume and brain atrophy. The examination of the cognitive impairment is usually based on particular neuropsychological batteries. However, it can be not enough to make a precise diagnosis. This creates a demand to find markers that might be useful for identifying patients with risk of cognitive impairment at an early stage of the disease. Currently the most promising methods consist of neuroimaging indicators, such as diffusion tensor imaging, the magnetization transfer ratio, and N-acetyl aspartate levels. Diagnosis problems are strictly connected with treatment procedures. There are two main cognitive therapies: pharmacological (disease modifying drugs (DMD), symptomatic treatments) and non-pharmacological interventions that are focused on psychological and physical rehabilitation. Some trials have shown a positive association between physical activity and the cognitive function. Conclusion: This article is an overview of the current state of knowledge related to cognition impairment treatment in MS. Additionally, novel strategies for cognitive impairments such as cryostimulation and other complementary methods are presented.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 50 条
  • [21] Non-pharmacological methods for reducing fatigue in Multiple Sclerosis (FAMUS)
    Lingard, N.
    Valkenborghs, S.
    Newton, K.
    Khormi, I.
    Ramadan, S.
    Lechner-Scott, J.
    Maltby, V. E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 35 - 35
  • [22] Non-pharmacological therapy options for chemotherapy-related cognitive impairment
    Piechowicz, Paulina
    Dunaj, Piotr
    Janota, Aleksandra
    Kolodziejczyk, Katarzyna
    Dzierzanowski, Tomasz
    [J]. MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2022, 14 (04): : 173 - 182
  • [23] Protection of cognitive impairment in older adults through non-pharmacological interventions
    Kim, Suk-hee
    Schneider, Catherine E.
    [J]. JOURNAL OF HUMAN BEHAVIOR IN THE SOCIAL ENVIRONMENT, 2022, 32 (05) : 629 - 645
  • [24] Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment
    Treanor, Charlene J.
    McMenamin, Una C.
    O'Neill, Roisin F.
    Cardwell, Chris R.
    Clarke, Mike J.
    Cantwell, Marie
    Donnelly, Michael
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (08):
  • [25] Non-Pharmacological Treatments of Neuropsychiatric Symptoms in Mild Cognitive Impairment (MCI)
    Thurin, Kristina
    Daffner, Kirk
    Gale, Seth
    Donovan, Nancy J.
    Urizar, Juan Carlos
    [J]. SEMINARS IN NEUROLOGY, 2022, 42 (02) : 192 - 203
  • [26] Cognitive Impairment Along the Course of Depression: Non-Pharmacological Treatment Options
    Listunova, Lena
    Roth, Corinna
    Bartolovic, Marina
    Kienzle, Johanna
    Bach, Claudia
    Weisbrod, Matthias
    Roesch-Ely, Daniela
    [J]. PSYCHOPATHOLOGY, 2018, 51 (05) : 295 - 305
  • [27] Pharmacological and non-pharmacological therapies as integral parts for optimizing patient outcomes
    Schreiner, A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S451 - S451
  • [28] The use of pharmacological and non-pharmacological cognitive enhancers in the Portuguese population
    Soares, Joana Maria
    Barbosa, Miguel
    [J]. PERFORMANCE ENHANCEMENT & HEALTH, 2024, 12 (01)
  • [29] The use of non-pharmacological therapies by pain specialists
    Berman, BM
    Bausell, RB
    [J]. PAIN, 2000, 85 (03) : 313 - 315
  • [30] Effects of non-pharmacological therapies for people with mild cognitive impairment. A Bayesian network meta-analysis
    Wang, Ying-quan
    Jia, Rui-xia
    Liang, Jing-hong
    Li, Jing
    Qian, Sheng
    Li, Jia-yu
    Xu, Yong
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2020, 35 (06) : 591 - 600